Tags

Type your tag names separated by a space and hit enter

Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation.
Fertil Steril 1997; 67(5):917-22FS

Abstract

OBJECTIVE

To assess the minimal effective dose of a GnRH antagonist (Cetrorelix; Asta Medical; Frankfurt, Germany) to prevent premature LH surge in patients undergoing controlled ovarian hyperstimulation (COH) for assisted reproductive technologies.

DESIGN

In 69 patients COH was carried out with the association of hMG, starting on day 2 of the menstrual cycle, and a GnRH antagonist (Cetrorelix) was administered from day 6 of the hMG treatment (day 7 of the menstrual cycle) every day up to and including the last day of the hMG injection. In 32 and 30 patients, 0.5 mg and 0.25 mg of Cetrorelix were administered, respectively. Seven patients received 0.1 mg of Cetrorelix.

SETTING

Tertiary referral center.

RESULT(S)

No premature endogenous LH surge occurred in patients treated with 0.5 and 0.25 mg of Cetrorelix, and serum LH concentrations were maintained constantly low during the entire follicular phase in both groups. Follicle-stimulating hormone, LH, E2, and P expressed as area under the curve were similar in both groups. A premature LH surge (18 mIU/mL; conversion factor to SI unit, 1.00) with a concomitant P rise (1.7 micrograms/L; conversion factor to SI unit, 3.180) occurred in one of the seven patients treated with 0.1 mg Cetrorelix; therefore, treatment with this dose was discontinued.

CONCLUSION(S)

The minimal effective dose of Cetrorelix able to prevent premature LH surge in COH cycles is 0.25 mg administered daily.

Authors+Show Affiliations

Centre for Reproductive Medicine, Dutch-speaking Brussels Free University, Belgium.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

9130900

Citation

Albano, C, et al. "Comparison of Different Doses of Gonadotropin-releasing Hormone Antagonist Cetrorelix During Controlled Ovarian Hyperstimulation." Fertility and Sterility, vol. 67, no. 5, 1997, pp. 917-22.
Albano C, Smitz J, Camus M, et al. Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation. Fertil Steril. 1997;67(5):917-22.
Albano, C., Smitz, J., Camus, M., Riethmüller-Winzen, H., Van Steirteghem, A., & Devroey, P. (1997). Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation. Fertility and Sterility, 67(5), pp. 917-22.
Albano C, et al. Comparison of Different Doses of Gonadotropin-releasing Hormone Antagonist Cetrorelix During Controlled Ovarian Hyperstimulation. Fertil Steril. 1997;67(5):917-22. PubMed PMID: 9130900.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation. AU - Albano,C, AU - Smitz,J, AU - Camus,M, AU - Riethmüller-Winzen,H, AU - Van Steirteghem,A, AU - Devroey,P, PY - 1997/5/1/pubmed PY - 1997/5/1/medline PY - 1997/5/1/entrez SP - 917 EP - 22 JF - Fertility and sterility JO - Fertil. Steril. VL - 67 IS - 5 N2 - OBJECTIVE: To assess the minimal effective dose of a GnRH antagonist (Cetrorelix; Asta Medical; Frankfurt, Germany) to prevent premature LH surge in patients undergoing controlled ovarian hyperstimulation (COH) for assisted reproductive technologies. DESIGN: In 69 patients COH was carried out with the association of hMG, starting on day 2 of the menstrual cycle, and a GnRH antagonist (Cetrorelix) was administered from day 6 of the hMG treatment (day 7 of the menstrual cycle) every day up to and including the last day of the hMG injection. In 32 and 30 patients, 0.5 mg and 0.25 mg of Cetrorelix were administered, respectively. Seven patients received 0.1 mg of Cetrorelix. SETTING: Tertiary referral center. RESULT(S): No premature endogenous LH surge occurred in patients treated with 0.5 and 0.25 mg of Cetrorelix, and serum LH concentrations were maintained constantly low during the entire follicular phase in both groups. Follicle-stimulating hormone, LH, E2, and P expressed as area under the curve were similar in both groups. A premature LH surge (18 mIU/mL; conversion factor to SI unit, 1.00) with a concomitant P rise (1.7 micrograms/L; conversion factor to SI unit, 3.180) occurred in one of the seven patients treated with 0.1 mg Cetrorelix; therefore, treatment with this dose was discontinued. CONCLUSION(S): The minimal effective dose of Cetrorelix able to prevent premature LH surge in COH cycles is 0.25 mg administered daily. SN - 0015-0282 UR - https://www.unboundmedicine.com/medline/citation/9130900/Comparison_of_different_doses_of_gonadotropin_releasing_hormone_antagonist_Cetrorelix_during_controlled_ovarian_hyperstimulation_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0015028297814070 DB - PRIME DP - Unbound Medicine ER -